ascopubs.org

Randomized study of darbepoetin alfa as modifier of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): Final outcome of the DAHANCA 10 ...

Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN No significant financial relationships to disclose. This ...
FierceBiotech

PRESS RELEASE: Phase 2 Study Suggests That Extended Dosing of Aranesp is as Efficacious as Weekly Dosing

BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...
News Medical

Test document

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...
EurekAlert!

New study on darbepoetin shows how to best reduce the need for blood transfusions in premature babies

A new study published in the Journal of Perinatology is helping premature babies avoid blood transfusions, thanks to new research and collaboration between researchers at Intermountain Health in Salt ...
ascopubs.org

Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy ...

Prechemotherapy hemoglobin (Hgb) and cognitive impairment among breast cancer patients This is an ASCO Meeting Abstract from the 2005 ASCO Annual Meeting. This abstract does not include a full text ...